Screening for speech and language delay in preschool children

Nelson H D, Nygren P, Walker M, Panoscha R
Record ID 32006000147
English
Authors' objectives:

The aim of this review was to determine the strengths and limits of evidence about the effectiveness of selecting, testing, and managing children with potential speech and language delay in the course of routine primary care. Key questions examined a chain of evidence about the accuracy and feasibility of screening children age 5 years and younger in primary care settings, role of risk factors in selecting children for screening, effectiveness of interventions for children identified with speech and language delay, and adverse effects of screening and interventions.

Authors' results and conclusions: Studies were summarized by descriptive methods and rated for quality using criteria developed by the U.S. Preventive Services Task Force (USPSTF). A large descriptive literature of potential risk factors for speech and language delay in children is heterogeneous and results are inconsistent. A list of specific risk factors to guide primary care physicians in selective screening has not been developed or tested. The most consistently reported risk factors include a family history of speech and language delay and learning difficulties, male sex, and perinatal factors. A total of 44 studies about evaluations taking 30 minutes or less to administer that could be administered in a primary care setting were considered to have potential for screening purposes. Studies included many different instruments, there were no accepted gold standards or referral criteria, and few studies compared the performance of 2 or more tests. Studies utilizing evaluations taking 10 minutes or less and rated good to fair in quality reported wide ranges of sensitivity and specificity when compared to reference standards (sensitivity 17% to 100%; specificity 45% to 100%). Studies did not provide enough information to determine how accuracy varied by age, setting, or administrator. Fourteen good and fair-quality randomized controlled trials of interventions reported significantly improved speech and language outcomes compared to control groups. Improvement was demonstrated in several domains including articulation, phonology, expressive language, receptive language, lexical acquisition, and syntax among children in all age groups studied and across multiple therapeutic settings. Improvement in other functional outcomes, such as socialization skills, self-esteem, and improved play themes, were demonstrated in some, but not all, of the 4 studies measuring them. In general, studies of interventions were small, heterogeneous, may be subject to plateau effects, and reported short-term outcomes based on various instruments and measures. As a result, long-term outcomes are not known, interventions could not be directly compared, and generalizability is questionable.
Authors' recommendations: Use of risk factors to guide selective screening is not supported by studies. Several aspects of screening have been inadequately studied to determine optimal methods including what instrument to use, what age to screen, and what interval is most useful. Trials of interventions demonstrate improvement in some outcome measures, but conclusions and generalizability are limited. Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians prior to referral for diagnostic evaluation, non speech and language and long-term benefits of interventions, adverse effects of screening and interventions, and cost.
Authors' methods: Review
Details
Project Status: Completed
Year Published: 2006
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Child, Preschool
  • Mass Screening
  • Language Development Disorders
Contact
Organisation Name: Agency for Healthcare Research and Quality
Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name: martin.erlichman@ahrq.hhs.gov
Contact Email: martin.erlichman@ahrq.hhs.gov
Copyright: Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.